LEN, which has demonstrated clinical efficacy in multiple myeloma and striking activity in myelodysplastic syndrome (MDS), can upregulate RUNX1 in hematopoietic stem and progenitor cells (24). The gene discussed is RUNX1; the disease is AL amyloidosis.